---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-034768"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T22:00:01.664454+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VYNE Therapeutics reports FY2021 revenue $14.8M, net loss $73.3M; pipeline progress

## Summary
- FY2021 revenue $14.8M (down 30% YoY); net loss $73.3M, adjusted net loss $65.2M; EPS -$1.42.
- FMX114 Phase 1b showed acceptable safety/PK; Phase 2a top-line results expected Q2 2022.
- VYN201 preclinical data in TH17, fibrosis, vitiligo models show significant improvement; IND/H2 2022.
- Divested MST franchise to Journey Medical for $20M upfront + $5M in 1 yr + up to $450M milestones.
- Prepaid $35M debt in Aug 2021; entered $30M equity purchase agreement with Lincoln Park Capital.

## SEC filing metadata
- accession: 0001104659-22-034768
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465922034768/0001104659-22-034768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465922034768/tm228420d5_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-034768
- JSON: https://secwatch.observer/filing/0001104659-22-034768.json
- Plain text: https://secwatch.observer/filing/0001104659-22-034768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.